| Autor: |
Laura D, Zambrano, Margaret M, Newhams, Samantha M, Olson, Natasha B, Halasa, Ashley M, Price, Julie A, Boom, Leila C, Sahni, Satoshi, Kamidani, Keiko M, Tarquinio, Aline B, Maddux, Sabrina M, Heidemann, Samina S, Bhumbra, Katherine E, Bline, Ryan A, Nofziger, Charlotte V, Hobbs, Tamara T, Bradford, Natalie Z, Cvijanovich, Katherine, Irby, Elizabeth H, Mack, Melissa L, Cullimore, Pia S, Pannaraj, Michele, Kong, Tracie C, Walker, Shira J, Gertz, Kelly N, Michelson, Melissa A, Cameron, Kathleen, Chiotos, Mia, Maamari, Jennifer E, Schuster, Amber O, Orzel, Manish M, Patel, Angela P, Campbell, Adrienne G, Randolph, Cindy, Bowens |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Morbidity and Mortality Weekly Report |
| ISSN: |
1545-861X |
| Popis: |
Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In the United States, the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged ≥16 years (4). Prelicensure randomized trials in persons aged ≥5 years documented high vaccine efficacy and immunogenicity (5) |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
